Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects

Fig. 1

Arithmetic mean plasma concentration–time profiles of lucerastat in healthy subjects after administration of a single oral dose of 100, 300, 500, and 1000 mg lucerastat, or two oral doses of 1000 mg lucerastat separated by 12 h (linear and semilogarithmic scales, 0–48 h). (Per–protocol set)

Back to article page